Karin Holmsten
Stockholm, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Exploring novel genomic biomarkers for response and survival after neoadjuvant chemotherapy and radical cystectomy of muscle-invasive bladder cancer.
Journal: ESMO open
Published: March 24, 2025
Impact of glucocorticoid treatment and clinical prognostic factors for outcome in patients with advanced urothelial cancer treated with pembrolizumab.
Journal: Urologic oncology
Published: December 06, 2024
Rising incidence trends of synchronous prostate and rectal cancers: a population-based study.
Journal: Acta oncologica (Stockholm, Sweden)
Published: November 28, 2024
Molecular Subtypes Are Associated With Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer Patients.
Journal: JCO precision oncology
Published: September 30, 2024
Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experience.
Journal: Radiation oncology (London, England)
Published: April 22, 2024
Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P).
Journal: BJU international
Published: March 12, 2024
Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer.
Journal: International journal of cancer
Published: May 09, 2023
Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era.
Journal: Clinical genitourinary cancer
Published: February 03, 2023
The optimal neoadjuvant chemotherapy regime for muscle-invasive bladder cancer: still an open question?
Journal: Acta oncologica (Stockholm, Sweden)
Published: December 09, 2022
Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome.
Journal: Molecular oncology
Published: January 07, 2022
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
Journal: European urology
Published: December 15, 2021
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
Journal: European urology
Published: July 10, 2021
Last Updated: 09/26/2026